CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dermavant Sciences, Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dermavant Sciences, Ltd.
3780 Kilroy Airport Way
Suite 250
Long Beach, CA  90806  United States

On 9/6/2019, the Company filed a Registration Withdrawal Request of its Form S-1 (File No. 333-231757) with the SEC, initially filed with the Commission on May 24, 2019.
This company is no longer actively traded on any major stock exchange.

Business Summary
Dermavant Sciences, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics in medical dermatology. The Company is developing its lead product candidate tapinarof as a differentiated therapeutic aryl hydrocarbon receptor modulating agent, or TAMA, topical cream for the treatment of psoriasis and atopic dermatitis. The Company’s products include tapinarof (DMVT-505), cerdulatinib (DMVT-502), oxybutynin (DMVT-504), DMVT-503 and lotamilast Gel (DMVT-501). The Company has commenced two pivotal Phase II clinical trials of tapinarof for the treatment of psoriasis.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20193/31/2019YesYes--Yes

Business Names
Business Name
40D
Dermavant Holdings Limited
Dermavant Sciences GmbH
Dermavant Sciences, Inc.
DRMT

General Information
Outstanding Shares: 24,539,383 (As of 6/10/2019)
Stock Exchange: FRA


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023